Developing choices for women at high risk of ovarian cancer: A briefing paper from The Eve Appeal
The conclusions are significant. For women not yet willing to undergo risk-reducing surgery, the screening programme developed by UK FOCSS appears to offer the best chance of avoiding being diagnosed with a very advanced cancer. Therefore, screening along with continued discussions about the need for risk-reducing surgery is an option for such women.Read More
Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study
Conclusion of the Authors: ROCA-based screening is an option for women at high risk of ovarian cancer/fallopian tube cancer who defer or decline risk reducing salpingo-oophorectomy, given its high sensitivity and significant stage shift. However, it remains unknown whether this strategy would improve survival in screened high-risk women.Read More
Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS.
Postmenopausal women aged 50-74 were randomised (1:1:2 ratio) to annual multimodal (MMS) using the Risk of Ovarian Cancer Algorithm (ROCA) or ultrasound (USS) screening, or no screening (control, C). Women with abnormal screens had repeat tests and those with persistent abnormality underwent clinical evaluation and, where appropriate, surgery.Read More
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian cancer mortality.Read More
UKCTOCS reports its first mortality analysis, potential for long term clinical benefit.
Data published in The Lancet today by one of the largest ever randomized trials has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20% after follow up of up to 14 years. Longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective.Read More